Reich K, Simpson EL, Langley R, Warren RB, Costanzo A, Saeki H, Almgren P, Gjerum L, Carlsson A, Gooderham M, Pinter A, de Bruin-Weller M, Blauvelt A. Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. J of Skin [Internet]. 2022 Nov. 16 [cited 2024 Jul. 3];6(6):s79. Available from: https://jofskin.org/33014/index.php/skin/article/view/1837